Overview
BSX market data
Price History
BSX price chart
Valuation & Profitability
- P/E (TTM)
- 20.40 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.94 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.59 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 0.0% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 17.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $42.20 – $109.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $75B · P/B 5.83 · P/S 3.57.
Company News
Boston Scientific CEO Mahoney Buys More Than 200k Shares for $10 Million. What Does This Mean for Investors in 2026?The Motley Fool · Aug 10, 2026, 6:15 PM
Boston Scientific shares are trading higher after a Form 4 filing indicated that the CEO bought 186,240 shares at an average price of $48.33 per share.Benzinga · Aug 6, 2026, 4:39 PM
Boston Scientific CEO Mahoney Purchased 186,240 Shares @Avg Price Of $48.33/Share As Reported In Form 4 FilingBenzinga · Aug 5, 2026, 8:23 PM
Shares of medical device and equipment companies are trading higher as investors assess the key takeaways from last week's financial results across the sector.Benzinga · Aug 3, 2026, 6:13 PM
Argus Research Downgrades Boston Scientific to HoldBenzinga · Jul 31, 2026, 11:25 AM
UBS Maintains Buy on Boston Scientific, Lowers Price Target to $67Benzinga · Jul 30, 2026, 8:25 PM
Citigroup Maintains Buy on Boston Scientific, Lowers Price Target to $61Benzinga · Jul 30, 2026, 6:17 PM
RBC Capital Maintains Outperform on Boston Scientific, Lowers Price Target to $70Benzinga · Jul 30, 2026, 5:26 PM
TD Cowen Maintains Buy on Boston Scientific, Lowers Price Target to $56Benzinga · Jul 30, 2026, 3:46 PM
Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $66Benzinga · Jul 30, 2026, 3:42 PM